5 citations,
November 2012 in “The Journal of Urology” Early hair loss may indicate future prostate issues.
5 citations,
January 2010 in “Acta Chirurgica Iugoslavica” Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.
4 citations,
June 2017 in “Endocrine Reviews” Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.
4 citations,
April 2020 in “Reports of Practical Oncology & Radiotherapy” Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.
Higher free testosterone levels can increase bone density and decrease body fat but may raise the risk of prostate cancer, hair loss, and benign prostate enlargement.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
3 citations,
January 2008 in “Endocrine journal” A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.
3 citations,
May 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
3 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
2 citations,
November 2023 in “International Journal of Preventive Medicine and Health (IJPMH)” The Unani Pharmacopoeia-Based Formulation significantly improved symptoms of enlarged prostate in rats.
2 citations,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
2 citations,
June 2022 in “Molecules” Connarus semidecandrus Jack extract promotes hair growth and thickness, reduces prostate cancer cell growth, and could potentially be used as a treatment for hair loss.
2 citations,
September 2020 Long-term high testosterone levels can improve bone density and reduce body fat but may increase the risk of prostate cancer and high blood pressure.
2 citations,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
2 citations,
April 2007 in “Journal of Labelled Compounds and Radiopharmaceuticals” The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
1 citations,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
1 citations,
May 2021 in “Problemy e̊ndokrinologii” Androgen levels can increase at any age, affecting symptoms like acne, hair loss, and prostate size.
1 citations,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
1 citations,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
September 2022 in “Archivio italiano di urologia, andrologia” Prostate surgery is often effective long-term, but some patients may need more treatment or another surgery, especially if they had prostatitis before.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
Increased free testosterone can lead to stronger bones and less body fat but also higher risks of prostate cancer, hair loss, spine issues, and high blood pressure.
October 2017 in “Universidad Nacional de Trujillo” Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early baldness in men may indicate a higher risk of prostate cancer.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early-onset male baldness may indicate a higher risk of prostate cancer.
June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
Finasteride reduces prostate size and PSA levels in young patients.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.